Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
COA published
- Arrives Fri, Oct 23 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
Recon Water
Research Supplies
Water with 0.9% benzyl alcohol added as a preservative, supplied in a 10 ml multi-dose vial. It is used to reconstitute lyophilized research peptides and keeps a vial usable across repeated draws. For in vitro laboratory research use only.
- Arrives Fri, Oct 23 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
Certificate of Analysis
Third Party Tested ISO/IEC 17025 ACCREDITED
Compound Information
What is Recon Water?
Stability information
- Protect from light
- Do not freeze
- Multi-dose vial
Conditions apply to sealed research vials as supplied. Batch details are on the Certificate of Analysis above.
Sources & References
Peer-reviewed research
Incompatibility of ifosfamide with benzyl-alcohol-preserved bacteriostatic water for injection
View Source ↗Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site
View Source ↗Antimicrobial preservative use in parenteral products: past and present
View Source ↗Benzyl alcohol adverse effects in the rat: implications for toxicity as a preservative in parentral injectable solutions
View Source ↗Antimicrobial Excipient-Induced Reversible Association of Therapeutic Peptides in Parenteral Formulations
View Source ↗Separation and identification of impurities in parenteral methotrexate dosage forms
View Source ↗Daptomycin: a comparison of two intravenous formulations
View Source ↗Safety in immediate reconstitution of poly-l-lactic acid for facial biostimulation treatment
View Source ↗Getting the most out of low-dose syringe prefilling of a high-cost biotechnology agent
View Source ↗Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
View Source ↗In vitro stability and compatibility of tenecteplase in central venous access devices
View Source ↗Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations
View Source ↗Frequently Researched Together
Related research compounds
GLP-3 (RT)
Triple-agonist metabolic research peptide
ARA-290
Cellular Peptide
BPC-157
Body-protective compound peptide
TB-500
Actin-binding research peptide
Glutathione
Antioxidant & Detoxification Peptide
GHK-Cu
Copper-binding tripeptide
Tesamorelin
GHRH analog
IGF-1 LR3
Long-acting IGF-1 analog
KLOW
Cellular Peptide Blend